IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$1.31 USD
+0.04 (3.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.31 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IGMS 1.31 +0.04(3.15%)
Will IGMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IGMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IGMS
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
IGMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Other News for IGMS
IGM Biosciences (IGMS) Shares Surge After Acquisition Announcement
IGM Biosciences climbs on merger deal with Concentra
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1. ...
IGM Biosciences be acquired by Concentra for $1.247 in cash per share
IGM Biosciences moved to No Rating at BofA